Axsome Therapeutics Inc (STU:19X)
€ 81.28 -1.42 (-1.74%) Market Cap: 3.94 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 40.50 GF Score: 36/100

Q3 2023 Axsome Therapeutics Inc Earnings Call Transcript

Nov 06, 2023 / 01:00PM GMT
Release Date Price: €59.32 (-2.40%)
Operator

Good morning, and welcome to Axsome Therapeutics Third Quarter 2023 Financial Results Conference Call. (Operator Instructions). As a reminder, today's conference is being recorded.

I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer, Axsome Therapeutics. Thank you. Please go ahead.

Mark L. Jacobson
Axsome Therapeutics, Inc. - COO & Secretary

Good morning, and thank you all for joining us on today's conference call. This morning, we issued our earnings press release providing a corporate update and details of the company's financial results for the third quarter of 2023. The release crossed the wire a short time ago and is available on our website at axsome.com. During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents, our clinical and nonclinical plans, our plans to present or report additional data, the anticipated conduct and the source

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot